BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Votrient pazopanib regulatory update

The U.K.'s NICE issued final guidance recommending the use of Votrient pazopanib from GlaxoSmithKline as a first-line treatment for patients with advanced renal cell carcinoma (RCC) who have not received prior cytokine therapy. The guidance is in line with...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >